Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

NCT01763905 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

307

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia

Interventions

BIOLOGICAL: Evolocumab
DRUG: Placebo to Evolocumab
DRUG: Ezetimibe
DRUG: Placebo to Ezetimibe

Sponsor

Amgen